PCSK9 inhibitors show superior LDL-C lowering effects to ezetimibe
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor is superior to ezetimibe in reducing low-density lipoprotein cholesterol (LDL-C),...
-
The potent and highly selective RET* inhibitor BLU-667 was well-tolerated and exhibited promising clinical activity among patients with adva...
-
Even in the long term, atezolizumab shows significant survival benefit over docetaxel for patients with advanced non-small–cell lung cancer ...
-
Individuals with major depressive disorder (MDD) have lower odds of testing seropositive for measles despite previous immunization, accordin...
No comments:
Post a Comment